Protaryx Medical is developing a first-in-class device to provide precision transseptal access to the left atrium during structural heart and catheter ablation procedures. The device offers independent steerability and three-dimensional control to streamline and improve accuracy of crossing to the left heart. It is designed for use in catheter-based procedures including mitral valve repair and replacement, left atrial appendage closure, and catheter ablation for cardiac arrhythmias. The company has completed non-dilutive grants and a seed round alongside a recently closed Series A to fund development. Leadership emphasizes simplifying transseptal access to reduce complications and improve patient outcomes. Protaryx is headquartered in Baltimore, Maryland, with engineering operations in Minneapolis, Minnesota, and its device is not available for sale.

Total raised

$8M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2020